Overview

Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial

Status:
NOT_YET_RECRUITING
Trial end date:
2030-08-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS (BI-DFS) and safety.
Phase:
PHASE2
Details
Lead Sponsor:
Renmin Hospital of Wuhan University